All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Financial Toxicity

May 7th 2013

A problem for many people undergoing cancer treatment.

Herbert Irving Comprehensive Cancer Center Joins OncLive's Strategic Alliance Partnership

May 7th 2013

OncLive is pleased to announce that the Herbert Irving Comprehensive Cancer Center has joined its Strategic Alliance Partnership program. This program enables the Herbert Irving Comprehensive Cancer Center to promote its institution and faculty as leaders in oncology to a national audience of oncology professionals.

ODAC Turns Down Chemosaturation System

May 2nd 2013

Citing concerns about the safety profile of the device, ODAC unanimously recommended against the approval of the Melblez chemosaturation system for use with melphalan hydrochloride in the treatment of patients with ocular melanoma metastasized to the liver.

ODAC Votes Against Tivozanib in Renal Cell Carcinoma

May 2nd 2013

A single clinical trial was deemed insufficient to support approval of tivozanib for the treatment of patients with advanced renal cell carcinoma, according to a 13-1 vote by the FDA's Oncologic Drugs Advisory Committee.

Breakthrough Designation Granted to Daratumumab for Double Refractory Multiple Myeloma

May 1st 2013

An investigational monoclonal antibody called daratumumab has received breakthrough therapy designation from the FDA for the treatment of patients with double refractory multiple myeloma.

PD-1 Targeted Antibody Lambrolizumab Receives FDA Breakthrough Designation

April 25th 2013

Lambrolizumab, an investigational antibody designed to target the programmed death-1 (PD-1) pathway in patients with melanoma, received a breakthrough therapy designation from the FDA after promising results from a small single-arm study.

Denial of Need for Long-Term Care Will Impact Healthcare System

April 25th 2013

Few baby boomers are facing the facts about aging.

US Supreme Court Hears Arguments in BRCA1/2 Patenting Case

April 18th 2013

The question of whether it should be legal to patent genes has reached the US Supreme Court, and the impending decision by the highest federal court in the country could significantly transform the current research landscape.

New Drug Potentially Blocks HPV from Causing Head and Neck Cancer

April 17th 2013

A novel small molecule inhibitor called CH1iB may be able to block a mechanism that enables human papilloma virus to cause head and neck cancer.

Trials in Progress: Bone Metastases

April 16th 2013

The Trials in Progress series is intended to stimulate discussion about ongoing clinical trials, to promote collaboration across the oncology community.

Microwave Ablation Is Potentially Effective in Treating Bone and Soft-Tissue Tumor Pain

April 15th 2013

A small study found that microwave ablation therapy reduced pain associated with bone and soft tissues by half in the majority of patients treated with the technique.

Chime in on Oral Cancer Screening Recommendations

April 15th 2013

USPSTF is inviting comments on screening by primary care professionals.

Palbociclib Receives Breakthrough Designation for Treatment of Breast Cancer

April 10th 2013

The drug palbociclib (formerly known as PD-0332991) has received has received a "breakthrough therapy designation" from the FDA for the treatment of patients with breast cancer.

AACR Rally Protests Cuts to NIH Budget

April 8th 2013

Sign-toting scientists, students, patients, and caregivers gathered near the Carnegie Library in Washington, DC, to protest recent cuts to the budget of the National Institutes of Health, the largest funder of medical research in the world.

Ibrutinib Receives Additional Breakthrough Designation for CLL

April 8th 2013

After receiving breakthrough therapy designation from the FDA for the treatment of two B-cell malignancies earlier this year, ibrutinib has received an additional breakthrough designation.

Melanoma

April 8th 2013

Melanoma is on the rise in children and teenagers.

Medicare Reimbursement Cuts Caused by Sequestration Begin to Take Effect

April 4th 2013

As a result of sequestration-related federal budget cuts, Medicare reimbursement has been reduced by 2% across the board, with the reduction affecting a number of services offered to cancer patients.

OncLive Collaborates With Renowned Cancer Centers

April 2nd 2013

Dana-Farber Cancer Institute and Seattle Cancer Care Alliance Join OncLive's Strategic Alliance Partnership Program.

Good News for Cancer Survivorship

March 25th 2013

The number of cancer survivors in the US continues to rise.

Novel Oncolytic Virus Effective in Melanoma

March 22nd 2013

The novel immunotherapy talimogene laherparepvec has become the first oncolytic virus to successfully complete a phase III trial in advanced melanoma.